| Literature DB >> 31416144 |
Marlene Hager1, René Wenzl2, Sonja Riesenhuber1, Julian Marschalek1, Lorenz Kuessel2, Daniel Mayrhofer1, Robin Ristl3, Christine Kurz1, Johannes Ott4.
Abstract
To evaluate the incidence of endometriosis in polycystic ovary syndrome (PCOS) patients who did not present with any endometriosis symptoms and underwent laparoscopic ovarian drilling (LOD) for clomiphene citrate (CC) resistance, 225 and 630 women with CC-resistant PCOS without classic endometriosis symptoms were included in a retrospective study and a meta-analysis, respectively. All women underwent LOD. The main outcome parameter was the prevalence of incidental endometriosis. Laparoscopy revealed endometriosis in 38/225 (16.9%) women (revised American Fertility Society (rAFS) stage I: 33/38, 86.8%; rAFS stage II: 5/38, 13.2%). When women with CC-resistant PCOS without endometriosis were compared, lower body mass index (BMI) and lower 25-hydroxy-vitamin D levels were associated with the presence of endometriosis at laparoscopy (odds ratios (OR): 0.872, 95% confidence intervals (95%CI): 0.792-0.960; p = 0.005 and OR: 0.980, 95%CI: 0.962-0.999; p = 0.036; respectively). The inclusion criteria for the meta-analysis were fulfilled by 4/230 reports about LOD. After correction for study heterogeneity, the pooled prevalence of incidental endometriosis was 7.7% in women with CC-resistant PCOS. In conclusion, the rate of incidental endometriosis in women with CC-resistant PCOS might reflect the prevalence of asymptomatic endometriosis. All cases were affected by minimal or mild disease. Since the literature lacks reports on associated clinical outcomes, the relevance of this entity in such patients should be the subject of further studies.Entities:
Keywords: endometriosis, ovarian drilling; laparoscopy; polycystic ovary syndrome; transvaginal hydrolaparoscopy
Year: 2019 PMID: 31416144 PMCID: PMC6722764 DOI: 10.3390/jcm8081210
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Studies about endometriosis prevalence in women undergoing laparoscopic ovarian drilling included into the pooled analysis.
| First Author (year) | Women with PCOS ( | Study Design | Years | Characteristics of PCOS Patients | Women with Endometriosis ( | Additional Findings |
|---|---|---|---|---|---|---|
| Kriplani (2001) [ | 70 | Retrospective | ? | Anovulatory, CC resistant | 7 (10.0) | Endometriotic cyst in |
| Salah (2013) [ | 120 | Retrospective | ? | Anovulatory, CC resistant | 22 (18.3) | – |
| Zahiri Sorouri (2014) [ | 100 | Prospective | 2011–2012 | CC resistant | 1 (1.0) | – |
| El-Sayed (2017) [ | 100 | Prospective | 2015–2017 | CC resistant, BMI < 30 kg/m2, LH >10 IU/mL or LH/FSH ratio >2, free androgen index >4, normal oGTT | 1 (1.0) | – |
| Hager (2019) | 240 | Retrospective | 2008–2018 | Anovulatory, CC resistant, women without signs of endometriosis | 38 (16.9) | – |
Abbreviations used: CC, clomiphene citrate; BMI, body mass index; LH, luteinizing hormone; FSH, follicle stimulating hormone; oGTT, oral glucose tolerance test.
Figure 1The prevalence of incidental endometriosis in women with CC-resistant PCOS: Results of the meta-analysis.
Figure 2Funnel plot for the meta-analysis.
Estimates and 95% confidence intervals obtained in a leave-one-out sensitivity analysis. The calculations are performed as in the main analysis. However, in each round of the sensitivity analysis one study is not included.
| Estimate Random Effect (95% CI) | Estimate Pooled (95% CI) | |
|---|---|---|
| All studies included | 0.077 (0.018; 0.167) | 0.110 (0.085; 0.134) |
| Without Kriplani (2001) [ | 0.071 (0.007; 0.188) | 0.111 (0.085; 0.137) |
| Without Salah (2013) [ | 0.056 (0.006; 0.145) | 0.092 (0.067; 0.117) |
| Without Zahiri Sorouri (2014) [ | 0.101 (0.030; 0.204) | 0.128 (0.100; 0.157) |
| Without El-Sayed (2017) [ | 0.101 (0.030; 0.204) | 0.128 (0.100; 0.157) |
| Without Hager (2019) | 0.059 (0.004; 0.159) | 0.079 (0.053; 0.106) |
General patient characteristics and hormonal profile in women with CC-resistant PCOS with and without endometriosis.
| Women with Endometriosis ( | Women without Endometriosis ( | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) |
| Adjusted OR (95% CI) |
| |||
| Age (years) * | 28.5 ± 4.8 | 28.3 ± 5.0 | 1.009 (0.941; 1.083) | 0.792 | – | – |
| Body mass index (kg/m2) * | 23.3 ± 5.2 | 25.3 ± 4.6 | 0.905 (0.830; 0.987) | 0.024 | 0.872 (0.792; 0.960) | 0.005 |
| Primary sterility # | 30 (78.9) | 122 (65.2) | 0.501 (0.217; 1.155) | 0.105 | – | – |
| Thyroid stimulating hormone (IU/mL) * | 1.6 ± 1.0 | 1.7 ± 1.0 | 0.888 (0.587; 1.343) | 0.573 | – | – |
| Prolactin (ng/mL) | 11.7 ± 5.1 | 13.5 ± 7.1 | 0.954 (0.896; 1.017) | 0.151 | ||
| 25 OH vitamin D (nmol/L) | 35.0 ± 24.8 | 43.8 ± 22.3 | 0.982 (0.965; 0.999) | 0.049 | 0.980 (0.962; 0.999) | 0.036 |
| LH (mIU/mL) * | 11.6 ± 7.5 | 12.6 ± 9.9 | 0.987 (0.945; 1.031) | 0.553 | – | – |
| FSH (mIU/mL) * | 5.7 ± 2.3 | 5.6 ± 2.0 | 1.019 (0.851; 1.219) | 0.838 | – | – |
| Testosterone (ng/mL) * | 0.43 ± 0.24 | 0.48 ± 0.25 | 0.432 (0.080; 2.344) | 0.331 | – | – |
| DHEAS (µg/mL) | 2.60 ± 1.20 | 2.57 ± 1.15 | 1.020 (0.732; 1.420) | 0.909 | – | – |
| AMH (ng/mL) * | 9.1 ± 6.2 | 9.5 ± 7.6 | 0.992 (0.935; 1.052) | 0.783 | – | – |
Data are presented as * mean ± standard deviation for numerical parameters or as # numbers (frequencies) for categorical parameters. Abbreviations used: OR, odds ratio; AMH, anti-Mullerian hormone.